Skip to main content

07-17-2018 | Heart failure | Article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Journal: Cardiovascular Diabetology

Authors: Ghadeer K. Dawwas, Steven M. Smith, Haesuk Park

Publisher: BioMed Central



Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management. Several studies have found cardioprotective effects of incretin-based therapies; however, it remains unclear whether there is any difference in heart failure (HF) risk between the two incretin-based therapies (DPP-4 inhibitors and GLP-1 receptor agonists). We aimed to assess the risk of hospitalization due to HF with the use of DPP-4 inhibitors compared to GLP-1 receptor agonists.


Using Truven Health Marketscan data, we conducted a retrospective cohort study of patients with type 2 diabetes, who were newly initiated on DPP-4 inhibitors or GLP-1 agonists. Follow-up continued from drug initiation until the first occurrence of: HF hospitalization (primary outcome), discontinuation of therapy (i.e. no fill for 7 days), switch to the comparator, end of enrollment, or end of study (December 2013). Cox proportional hazards models with propensity-score-matching were used to compare the risk of HF hospitalization between DPP-4 inhibitors and GLP-1 agonists.


A total of 321,606 propensity score-matched patients were included in the analysis (n = 160,803 for DPP-4 inhibitors; n = 160,803 for GLP-1 agonists). After adjusting for baseline characteristics and disease risk factors, the use of DPP-4 inhibitors was associated with a 14% decreased risk of HF hospitalization compared to GLP-1 agonists use [hazard ratio (HR), 0.86; 95% confidence interval (CI) 0.83, 0.90]. The results were consistent in patients without baseline HF (HR, 0.85; 95% CI 0.82, 0.89), but the association was not statistically significant for patients with baseline HF (HR, 0.90; 95% CI 0.74, 1.07).


In this retrospective matched cohort of patients with type 2 diabetes, the use of DPP-4 inhibitors was associated with a reduced risk of HF hospitalization compared to GLP-1 agonists. However, the association was not statistically significant in patients who had HF prior to the use of DPP-4 inhibitors.
Filion KB, Suissa S. DPP-4 inhibitors and heart failure: some reassurance, some uncertainty. Diabetes Care. 2016;39(5):735–7. https://​doi.​org/​10.​2337/​dci15-0036.CrossRefPubMed
Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164(11):705–14. https://​doi.​org/​10.​7326/​m15-2568.CrossRefPubMedPubMedCentral
Vella A. Mechanism of action of DPP-4 inhibitors–new insights. J Clin Endocrinol Metab. 2012;97(8):2626–8. https://​doi.​org/​10.​1210/​jc.​2012-2396.CrossRefPubMedPubMedCentral
Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: Systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610. https://​doi.​org/​10.​1136/​bmj.​i610.CrossRefPubMedPubMedCentral
Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014;5(3):138–46. https://​doi.​org/​10.​1177/​2042098614523031​.CrossRefPubMedPubMedCentral
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. https://​doi.​org/​10.​1056/​nejmoa1307684.CrossRefPubMed
Zannad F, Stough WG, Lipicky RJ, et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):200–5. https://​doi.​org/​10.​1093/​ehjcvp/​pvw007.CrossRefPubMedPubMedCentral
Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://​doi.​org/​10.​1056/​nejmoa1501352.CrossRefPubMed
Food and Drug Administration. FDA drug safety communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. US Food and Drug Administration Web site. https://​www.​fda.​gov/​Drugs/​DrugSafety/​ucm486096.​htm. Updated 2016. Accessed 04 Apr 2018.
Fu AZ, Johnston SS, Ghannam A, et al. Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. 2016;39(5):726–34. https://​doi.​org/​10.​2337/​dc15-0764.CrossRefPubMed
American Diabetes Association. 8. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–85. https://​doi.​org/​10.​2337/​dc18-s008.CrossRef
Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: Is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557–67. https://​doi.​org/​10.​1111/​ijcp.​12361.CrossRefPubMedPubMedCentral
Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580–91. https://​doi.​org/​10.​1001/​jama.​2018.​3024.CrossRefPubMedPubMedCentral
Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):129–40. https://​doi.​org/​10.​1002/​pds.​2313.CrossRefPubMed
Fireman B, Toh S, Butler MG, et al. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):282–90. https://​doi.​org/​10.​1002/​pds.​2337.CrossRefPubMed
Yang D, Dalton J. A unified approach to measuring the effect size between two groups using SAS®. SAS Global Forum. 2012;35:1–6.
D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81. https://​doi.​org/​10.​1002/​(sici)1097-0258(19981015)17:​193.​0.​co;2-b.CrossRefPubMed
Kim YG, Yoon D, Park S, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study. Circ Heart Fail. 2017;10(9):e003957. https://​doi.​org/​10.​1161/​circheartfailure​.​117.​003957.CrossRefPubMed
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American heart association and American diabetes association. Diabetes Care. 2004;27(1):256–63.CrossRefPubMed
Fadini GP, Bonora BM, Albiero M, Zaninotto M, Plebani M, Avogaro A. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):22. https://​doi.​org/​10.​1186/​s12933-017-0507-9.CrossRefPubMedPubMedCentral
Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215. https://​doi.​org/​10.​1210/​er.​2011-1052.CrossRefPubMedPubMedCentral
Miyoshi T, Nakamura K, Yoshida M, et al. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol. 2014;13:43. https://​doi.​org/​10.​1186/​1475-2840-13-43.CrossRefPubMedPubMedCentral
Chin HJ, Nam JH, Lee EK, Shin JY. Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: a retrospective cohort study. Medicine (Baltimore). 2017;96(25):e7213. https://​doi.​org/​10.​1097/​md.​0000000000007213​.CrossRef
Hashikata T, Yamaoka-Tojo M, Kakizaki R, et al. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart Vessels. 2016;31(8):1303–10. https://​doi.​org/​10.​1007/​s00380-015-0724-7.CrossRefPubMed
Gautam S, Agiro A, Barron J, Power T, Weisman H, White J. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol. 2017;16(1):93. https://​doi.​org/​10.​1186/​s12933-017-0575-x.CrossRefPubMedPubMedCentral
Li L, Li S, Liu J, et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord. 2016;16:91. https://​doi.​org/​10.​1186/​s12872-016-0260-0.CrossRefPubMedPubMedCentral
Gargiulo P, Savarese G, D’Amore C, et al. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. Nutr Metab Cardiovasc Dis. 2017;27(12):1081–8.CrossRefPubMed
Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab. 2017;43(Suppl 1):2S13–9.CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »